Photoreceptor Protection by Cardiotrophin-1 in Transgenic Rats with the Rhodopsin Mutation S334ter

Abstract

purpose. This work examines the effects of cardiotrophin (CT)-1 on photoreceptor survival in transgenic rats that carry the rhodopsin mutation S334ter.

methods. Recombinant CT-1 was injected intravitreally into eyes of heterozygous animals. Photoreceptor survival was analyzed by histology. Phosphorylation of signal transducer and activator of transcription1 (STAT1), STAT3, extracellular signal-regulated kinase (ERK), or Akt was assessed by immunoblot analysis. Localization of phosphorylated STAT3 was determined by immunocytochemistry.

results. Heterozygous S334ter rats experience rapid photoreceptor degeneration. By postnatal day (PD)20, the outer nuclear layer (ONL) retained only 1 to 2 rows of nuclei compared with 10 to 12 rows in wild-type animals. Repeated administration of CT-1 resulted in significant survival of photoreceptors. At PD20, a CT-1–treated eye (2 μg/2 μL every 3 days, starting at PD9) had six to seven rows of nuclei, and the vehicle-treated eyes had only one to two rows. At PD30, eyes treated every 3 days still had five to six rows of nuclei, in contrast to no rows to one row in vehicle-treated eyes. Eyes treated every 4 days retained three to four rows, whereas eyes treated every 5 days had two to three rows. There was a significant increase in phosphorylated STAT1 and -3 in the retina after CT-1 injection. The increase in phosphorylated STAT3 was colocalized with glutamine synthetase, a Müller cell marker, by immunocytochemistry.

conclusions. These results indicate that CT-1 promotes photoreceptor survival and that Müller cells probably mediate this effect. They also suggest that sustained delivery of the protein is essential for long-term rescue of photoreceptors.

Retinitis pigmentosa is a group of inherited retinal degenerative disorders. In the early stage of the disease, patients typically experience night blindness and a decline in peripheral vision due to loss of rod photoreceptors. As the degeneration progresses, central vision is also affected, leading eventually to total blindness. Mutations in any one of many different genes can be responsible for photoreceptor degeneration, including rhodopsin, peripherin, the β subunit of the cGMP phosphodiesterase, and the rod outer segment protein ROM1. ^{1 2}  

In animal models of photoreceptor degeneration, photoreceptors are partially protected by neurotrophic factors. This was first demonstrated in the Royal College of Surgeon (RCS) rat in which a mutation in the Mertk gene renders the retinal pigment epithelial (RPE) cells incapable of proper phagocytosis, ^{3 4} resulting in accumulation of the shed outer segments of photoreceptors in the subretinal space and eventually to degeneration of the photoreceptors. Subretinal injection of basic fibroblast growth factor (bFGF) was found to rescue photoreceptors temporarily in the RCS rats. ⁵ Subsequent studies showed that ciliary neurotrophic factor (CNTF), a member of the interleukin (IL)-6 family of cytokines, protects photoreceptors in a broad range of animal models in several species, including rat, ⁶ mouse, ⁷ and dog. ⁸  

CT-1, also a cytokine of the IL-6 family, was originally identified as a factor that induces hypertrophy of cardiac myocytes. ⁹ Further characterization revealed that it also promotes cardiac myocyte survival ¹⁰ and supports the long-term survival of spinal motor neurons. ¹¹ Studies have shown that the biological effects of CT-1 are initiated by the binding of CT-1 to a receptor complex containing gp130 and leukemia inhibitory factor receptor (LIFR)-β, ¹² and are mediated through specific signaling pathways. CT-1 promotes survival of myocardial cells through the extracellular signal-regulated kinase (Erk)–mitogen-activated protein (MAP) kinase and the phosphatidylinositol 3 (PI3) kinase/Akt signaling pathways, ^{10 13} whereas it induces cardiac myocyte hypertrophy by activating a signal transducer and activator of transcription (STAT)-3–dependent pathway. ¹⁴  

The present work examines the potential of CT-1 to protect photoreceptors in a line of transgenic rats that carry the rhodopsin mutation S334ter. These animals experience rapid photoreceptor degeneration soon after birth. ¹⁵ Repeated intravitreal injection of CT-1 leads to greatly enhanced survival of photoreceptor cells in these animals. Results also show that CT-1 activates the STAT3 signaling pathway in retinal Müller cells. These findings suggest that long-term protection of photoreceptors could be achieved by sustained delivery of neurotrophic factors such as CT-1. They also indicate that CT-1 promotes photoreceptor survival indirectly through the agency of Müller cells. 

Materials and Methods

Expression and Purification of Recombinant CT-1 Protein

The open reading frame of human CT-1 cDNA was PCR cloned into an expression vector (pQE30; Qiagen, Valencia, CA), fused to a 6xHis tag at the amino terminus, to generate plasmid pQE-CT1. Recombinant human CT-1 protein was expressed in Escherichia coli (XL-blue; Stratagene, La Jolla, CA) and purified by immobilized-metal affinity chromatography on Ni-NTA agarose (Qiagen) columns under native conditions. Eluted protein was buffer-exchanged with phosphate-buffered saline (PBS), and its concentration determined by the BCA protein assay (Pierce, Rockford, IL). The purified recombinant protein has an apparent size of ∼22 kDa after electrophoresis on acrylamide gel (Fig. 1) . 

Animals and Intravitreal Injections

All procedures involving animals adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Homozygous breeders of line 3 of transgenic rats that carry a murine rhodopsin mutant S334ter were kindly provided by Matthew M. LaVail (University of California, San Francisco, CA). Animals were genotyped by PCR to confirm that they carried the transgene. The homozygosity was confirmed by mating each homozygous animal with a wild-type Sprague-Dawley rat and genotyping each offspring. In addition, the phenotype (rapid photoreceptor degeneration) of each offspring was confirmed. All animals used in the present work were heterozygous S334ter-3 rats produced by mating homozygous male breeders with wild-type Sprague-Dawley females. Age-matched wild-type Sprague-Dawley rats were used as the control. Animals were kept in a 12-hr light–dark cycle at an in-cage illuminance of less than 10 foot candles (1 ft-c, 10.76 lux). The in-cage temperature was kept at 20°C to 22°C. Intravitreal injections were delivered through 32-gauge needles connected to 10-μL microsyringes (Hamilton, Reno, NV). The right eye of an animal was injected with 2 μL of PBS as control and the left eye with 2 μg CT-1 (in 2 μL of PBS). Injection was given initially at postnatal day (PD)9 and repeated every 3, 4, or 5 days. Eyes were collected at PD20 or PD30. The numbers of transgenic animals used were as follows: five for single injection, end point PD20 (described in Figs. 2B 2C ); seven for multiple injections at 3-day intervals, end point PD20 (described in Fig. 2D ); nine for multiple injections at 3-day intervals, end point PD30 (described in Figs. 3B 3C ); five for multiple injections at 4-day intervals, end point PD30 (described in Fig. 3D ); and four for multiple injections at 5-day intervals, end point PD30 (described in Fig. 3E ). 

Histology and Immunocytochemistry

Animals were killed by CO₂ overdose, immediately followed by vascular perfusion with mixed aldehydes. ¹⁶ Eyes were embedded in an Epon/Araldite mixture, sectioned at 1 μm thickness to display the entire retina along the vertical meridian. ¹⁶ Retinal sections were examined by light microscopy. For immunocytochemical experiments, eyes were removed from animals after 4% paraformaldehyde perfusion, cryoprotected with 20% sucrose, frozen in OCT compound (Tissue-Tek; Miles Inc., Elkhart, IN) in powdered dry ice, and stored at −80°C. Tissue sections (10 μm) along the vertical meridian were cut on a cryostat at −20°C and thaw mounted onto glass slides (Super Frost Plus; Fisher Scientific, Pittsburgh, PA). Retinal sections were probed with anti-phospho-STAT3 (Tyr705) antibodies (Cell Signaling Technology, Beverly, MA). Immunoreactivity was visualized using an ABC kit (Vectastain ABC; Vector Laboratories, Burlingame, CA) and a tyramide signal amplification kit (TSA-Direct; NEN Life Science Products, Boston, MA) according to manufacturer’s instructions. Müller cells were identified by antibodies against glutamine synthetase (GS; Chemicon International, Temecula, CA), a Müller-cell–specific marker. GS immunoreactivity was visualized by Cy3-conjugated goat anti-mouse IgG secondary antibodies. Sections were examined by confocal microscopy. 

Antibodies, Protein Preparation, and Immunoblot Analysis

Antibodies against phospho-STAT3 (Tyr705), STAT3, phospho-STAT1 (Tyr701), STAT1, phospho-ERK (Thr202/Tyr204), ERK, phospho-AKT (Ser473), and AKT were purchased from Cell Signaling Technology. To prepare retinal total protein, retinas were dissected, snap frozen in powdered dry ice, and stored at −80°C. Pooled retinas were homogenized and the concentration of total protein in each sample was determined by the bicinchoninic acid (BCA) protein assay (Pierce). Total protein of 40 μg from each sample was electrophoresed on 10% polyacrylamide gel (NuPage; Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). Blots were stained briefly with ponceau S for visual inspection of transfer efficiency. Immunoblot analysis was performed, and signals were visualized using chemiluminescent substrates (SuperSignal; Pierce) and recorded on autoradiograph (Hyperfilm; Amersham). All experiments were repeated three times to verify the consistency of the results. 

Results

Protection of Photoreceptors by CT-1

Heterozygous transgenic rats that carry the rhodopsin mutation S334ter (the S334ter-3 rats) were used to evaluate the potential of CT-1 for photoreceptor protection. These animals experience rapid photoreceptor degeneration shortly after birth. Degeneration is evident as early as PD8, and by PD20 more than 90% photoreceptors are lost. ¹⁵ PD20 was therefore chosen as the end point for our routine screening for potential photoreceptor protective agents. Figure 2 shows representative superior retinal sections from control and S334ter-3 animals collected at PD20. In wild-type Sprague-Dawley rats, the outer nuclear layer (ONL) had 11 to 12 rows of photoreceptor nuclei and the inner and outer segments were well developed (Fig. 2A) . Severe degeneration was observed in PBS-treated eyes of transgenic animals. Shown in Figure 2B is a section of the superior retina of the right eye of an S334ter-3 rat that received a single injection of 2 μL PBS at PD9. It had only one row of nuclei in the ONL and very short inner segments with no visible outer segments. In the left eye of this animal, which was treated with a single intravitreal injection of CT-1 (2 μg in 2 μL PBS) at PD9, the retina retained two to three rows of nuclei in the ONL (Fig. 2C) . Repeated injection of the same dose at an interval of 3 days resulted in significant protection of photoreceptors. Figure 2D shows a superior retina from an eye that was treated with CT-1 every 3 days starting at PD9. The ONL still had six to seven rows of nuclei at PD20, and the inner segments were better preserved. Control retinas treated with PBS (2 μL) every 3 days (data not shown) were similar in appearance to the section in Figure 2B . 

The significant preservation of photoreceptors in CT-1–treated eyes at PD20 encouraged us to extend our experiments to PD30. Figure 3 shows representative tissue sections of superior retinas collected at PD30. The retinas of wild-type control rats at PD30 were similar to those in PD20 animals. The ONL generally had 10 to 12 rows of nuclei (Fig. 3A) . The retina from the right eye of a transgenic animal that was treated with PBS (2 μL every 3 days, starting at PD9) did not have enough nuclei in the ONL to form even a single continuous row. In many areas photoreceptor nuclei were completely missing (Fig. 3B) . The retina from the left eye of the same animal that received CT-1 every 3 days (2 μg in 2 μL PBS, starting at PD9), not only retained five to six rows of nuclei in the ONL, but the inner segments were better preserved as well (Fig. 3C) . When the injection interval was extended to 4 days, the protective effect, although diminished, was still significant (Fig. 3D) . Shown in Figure 3D is a retina treated with CT-1 every 4 days (2 μg in 2 μL PBS, starting at PD9) with three to four rows of nuclei in the ONL. The protective effect declined still further when the injection interval was extended to 5 days. Figure 3E shows a retina treated with CT-1 every 5 days (2 μg in 2 μL PBS, starting at PD9), with only two rows of nuclei in the ONL (Fig. 3E) . Although repeated treatment of CT-1 resulted in impressive preservation of the photoreceptor cell body, no clear outer segment development was observed, even at PD30. 

CT-1–Induced Phosphorylation of Signaling Proteins

Effects of CT-1 are mediated through specific signaling pathways: CT-1 promotes survival of myocardial cells through the MAP kinase and the PI3 kinase/Akt signaling pathways, whereas it induces cardiac myocyte hypertrophy through the STAT3 pathway. ^{10 13 14} To explore the signaling pathways through which CT-1 protects photoreceptors, we examined the phosphorylation state of proteins in several signaling pathways. In these experiments, S334ter-3 rats at PD9 were treated with PBS (2 μL) in the right eye and CT-1 (2 μg in 2 μL PBS) in the left eye. Retinas were collected at various time points after injection, and the amount of phosphorylated STAT1, STAT3, Erks, and Akt was examined by immunoblot analysis. As shown in Figure 4A , CT-1 induced a dramatic increase in STAT3 phosphorylation. The increase was detected as early as 30 minutes after injection and lasted 24 hours. A smaller increase of shorter duration in STAT3 phosphorylation was observed in PBS-injected retinas (Fig. 4B) . Injection of CT-1 also induced STAT1 phosphorylation of duration similar to that of STAT3 phosphorylation (Fig. 4C) . There was, however, no detectable increase in STAT1 phosphorylation in PBS-treated eyes (data not shown). 

A parallel increase was demonstrated in Erk1/2 phosphorylation in CT-1–treated retinas (Fig. 5A) . The increase reached its maximum within 1 hour, and by 12 hours it had already declined to a level close to control. PBS injection induced a small increase in Erk1/2 phosphorylation of a shorter duration (Fig. 5B) . CT-1 treatment did not alter Akt phosphorylation in the retina (Fig. 5C) , nor did PBS injection (data not shown). 

Localization of Phospho-STAT3

To localize the CT-1–induced increase in STAT3 phosphorylation, normal Sprague-Dawley rats were treated in the left eyes with CT-1 (2 μg in 2 μL PBS), and the untreated right eyes were the control. Eyes were collected 1 hour after treatment, and frozen sections (10 μm) were prepared for immunocytochemical analysis using phospho-STAT3–specific antibodies. In the control retina, immunostaining for phospho-STAT3 is detected mainly in the nuclei of retinal ganglion cells. Slight staining is also visible in some cells in the inner nuclear layer (INL; Fig. 6A ). A dramatic increase in phospho-STAT3 immunostaining in the CT-1–treated retina (left eye of the same animal, 1 hour after intravitreal injection of CT-1) was seen in a specific band of cells in the INL (Fig. 6B) . No significant alteration of the intensity of signals in the ganglion cells was observed, however. The location and morphology of the cells that responded to CT-1 treatment suggested that they were Müller cells. To confirm the identity of these cells, we performed double-labeling experiments using antibodies against phospho-STAT3 and glutamine synthetase (GS), a Müller-cell–specific marker. The immunostaining of phospho-STAT3 (Figs. 6C 6E , green) and GS (Figs. 6D 6E , red) are colocalized in cells (Fig. 6E , yellow) in which an increase in STAT3 phosphorylation was observed after CT-1 treatment. Thus, in our experiments, CT-1 induced STAT3 activation specifically in Müller cells. 

Discussion

Although retinal degenerative disorders have similar clinical manifestations—namely, the degeneration of rod photoreceptors, which eventually leads to cone degeneration and blindness—the underlying genetic abnormalities can be very different. ^{1 2} Given the genetic heterogeneity of retinitis pigmentosa, one practical treatment strategy would be to promote photoreceptor survival through a common mechanism, rather than to attempt to target a large number of specific mutations. Evidence is accumulating in this regard that activation of a gp130-dependent mechanism in Müller cells by neurotrophic factors, such as members of the IL-6 family of cytokines, represents a viable approach to treatment without identifying the specific gene mutation. Photoreceptor rescue by neurotrophic factors first came to prominence when it was demonstrated in the RCS rat that injection of bFGF protects photoreceptors. ⁵ Subsequently, a screen of a panel of neurotrophic factors in a second model, the light-damage model of photoreceptor degeneration in the albino rat, revealed the photoreceptor protective properties of CNTF. ⁶ Still later, studies showed that whereas some factors, such as bFGF, rescue photoreceptors in only one or a few animal models, CNTF is protective over a broad range of models and species. ^{6 7 8} The breadth of protection afforded by CNTF leads immediately to the hypothesis that a common mechanism exists in mammalian retina through which CNTF or CNTF-like molecules can promote photoreceptor survival. That mechanism probably involves a gp130-dependent signaling pathway. A recent report that cardiotrophin-like cytokine (CLC) protects photoreceptors is consistent with this hypothesis (Wen R, et al. IOVS 2001;42:ARVO Abstract 3380), as is the present work, which provides clear evidence that CT-1 also protects photoreceptors. Because all three are members of the IL-6 family of cytokines, it is very probable that they work by the same mechanism. 

CT-1, originally identified in a screening conducted to find factors that induce a hypertrophic response in neonatal cardiac muscle cells, ⁹ is a polypeptide of approximately 200 amino acid (aa) residues (human CT-1: 201 aa, mouse CT-1: 203 aa) with 80% amino acid identity between mouse and human. Similar to CNTF, the N-terminal of CT-1 does not have a conventional hydrophobic secretion signal sequence ^{9 17} although CT-1 is secreted nonetheless. ¹¹ Being a member of the IL-6 family of cytokines, CT-1 has 24% amino acid identity to LIF and 19% identity to CNTF. Analysis of the secondary structure predicted for CT-1 also indicates similarity with other members of the family. More important, CT-1 binds to a receptor complex containing LIFRβ and gp130, commonly shared by other members of the family. ¹² Functionally, CT-1 not only induces a hypertrophic response in cardiac myocytes, ^{9 17} but also has cytoprotective effect on them. ¹⁰ Expression of CT-1 mRNA is found to be high in heart and skeleton muscles, suggesting that CT-1 is also a candidate motor neuron survival factor. ^{9 17} Indeed, CT-1 supports long-term survival of spinal motor neurons. ¹¹  

CT-1 activates several signal transduction pathways. The cytoprotective effect of CT-1 on myocardial cells is clearly mediated through the Erk-dependent and the PI3 kinase/Akt pathways, ^{10 13 14} whereas the STAT3-dependent pathway is responsible for the hypertrophic response of cardiac muscle cells. ^{10 14} In the present work, intravitreal injection of CT-1 activated STAT1, STAT3, and Erks, entirely consistent with previous findings by Peterson et al. ¹⁸ that a CNTF mutein axokine also stimulates phosphorylation of STAT1, STAT3, and Erks. The localization of CT-1–induced phospho-STAT3 in Müller cells in the present work is consistent with the finding that axokine-induced STAT3 and Erk phosphorylation occurs in Müller cells. ¹⁸ These findings are consistent with the hypothesis that CT-1 acts through signaling pathways similar to those of CNTF in the retina and that Müller cells are the major target cells. 

An important finding of the present work concerns dose and regimen. Long-term protection of photoreceptors can be achieved by repeated injection of CT-1. For the potential clinical use of any neurotrophic factor, such as CNTF or CT-1, a crucial issue is whether the factor in question offers long-term protection, and if so, how best to achieve it. In the present work, we used an animal model with rapid photoreceptor degeneration. Photoreceptor death in these animals was evident as early as PD8 and by PD20, only 1 to 2 rows of photoreceptor nuclei remain in the ONL from the original 11 to 12 rows. The peak of degeneration occurs between PD10 and PD12 during which approximately 50% of photoreceptors disappeared. ¹⁵ Considering the rapidity and severity of the degeneration, it is surprising to see that nearly 50% of photoreceptors remained at PD30 (the arbitrary end point of these experiments) with repeated CT-1 injections at 3-day intervals. Of specific note, relatively few photoreceptors died between PD20 and PD30 with repeated CT-1 injections (every 3 days), indicating that such treatment effectively prevented the degenerative process. It is also worth noting that less of a protective effect was observed when the intervals were extended to 4 or 5 days and that the protective effect was roughly inversely proportional to the length of the interval (Fig. 3) . Two important points can be deduced from these observations: that the protein available to the responsive cells rapidly diminishes after a bolus injection and that the memory of the responsive cells is short. It is therefore reasonable to presume that more frequent treatment would result in enhanced protection. More to the point, maximum efficacy is likely to require sustained delivery. 

In summary, the present work demonstrates the photoreceptor protective properties of CT-1 and highlights the role of a gp130-dependent mechanism in Müller cells in photoreceptor protection. It also points out the potential importance of sustained delivery of neurotrophic factors such as CT-1 for long-term rescue of photoreceptors. 

 The confocal microscopy was performed in the F. M. Kirby Confocal Microscopy Laboratory of the Scheie Eye Institute, University of Pennsylvania, School of Medicine.

 Supported by National Eye Institute Grant EY12727, the Foundation Fighting Blindness, the Karl Kirchgessner Foundation, and the Paul and Evanina Mackall Foundation Trust.

 Submitted for publication November 5, 2002; revised March 5, 2003; accepted April 14, 2003.

 Disclosure: Y. Song, None; L. Zhao, None; W. Tao, Neurotech USA (E); A.M. Laties, None; Z. Luo, None; R. Wen, None

 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

 

Figure 1.

 

Recombinant human CT-1. Recombinant protein was purified on nickel columns. One microgram of purified protein was electrophoresed on 10% polyacrylamide gel and visualized with Coomassie blue. CT-1 protein was detected as a single band of ∼22 kDa. Lane 1: protein molecular mass marker (molecular mass is indicated on the left for the two bands near the CT-1 protein); lane 2: 1 μg of purified recombinant human CT-1 protein.

Figure 2.

 

Protection of photoreceptors by CT-1 (PD20). Plastic-embedded sections of retina from a normal rat (A), or retinas from transgenic rats treated with PBS (B), a single injection of CT-1 (C), or multiple injections of CT-1 (D) were examined at PD20 by light microscopy. The normal retina had well-developed outer and inner segments (OS, IS). The ONL had 11 to 12 rows of nuclei (A). In the PBS-treated retina (2 μL, single injection at PD9) from the right eye of an S334ter-3 rat, the ONL had only one row of nuclei, and the inner segments became very short stumps (B). In the retina treated with a single dose of CT-1 (2 μg in 2 μL PBS at PD9) from the left eye of the same animal (C), the ONL had two to three rows of nuclei. The ONL of a retina from a rat that received repeated injections every 3 days (2 μg CT-1 in 2 μL PBS per injection, starting at PD9) had six to seven rows of nuclei. The IS were better preserved, although shorter than those in normal control eyes. Some dislocated cells were found in the subretinal space next to the RPE (D). Sections were stained with toluidine blue. OPL, outer plexiform layer. Scale bar, 20 μm.

Figure 3.

 

Protection of photoreceptors by CT-1 (PD30). Plastic-embedded sections of retinas from a normal rat (A), or retinas from transgenic rats treated with PBS (B), or multiple injections of CT-1 (C, every 3 days; D, every 4 days; E, every 5 days) were examined at PD30 by light microscopy. The normal retina had 10 to 12 rows of nuclei and well-organized outer and inner segments (A). In the PBS-treated retina (2 μL every 3 days starting at PD9) from the right eye of a transgenic animal, the ONL had only one row of nuclei and in many places, photoreceptor nuclei were completely missing (B). In the retina from the left eye of the same animal that received CT-1 injections every 3 days (2 μg in 2 μL PBS per injection starting at PD9), the ONL had five to six rows of nuclei (C). In the retina that received injections every 4 days (2 μg in 2 μL PBS per injection starting at PD9), the ONL had three to four rows of nuclei (D). When treated with CT-1 every 5 days (2 μg in 2 μL PBS per injection starting at PD9), the retina still had two rows of nuclei in the ONL (E). Sections were stained with toluidine blue. OPL, outer plexiform layer. Scale bar, 20 μm.

Figure 4.

 

CT-1 induced phosphorylation of STAT3 and -1. Immunoblot analyses were performed to detect the phosphorylation of STAT3 and STAT1 at 0 (control), 0.5, 1, 6, 12, 24, and 48 hour after intravitreal injection of CT-1 (2 μg in 2 μL PBS) in PD9 S334ter-3 rats. (A) CT-1 induced a significant STAT3 phosphorylation (pSTAT3), which was detected as early as 30 minutes and lasted 24 hours. It also induced a slight increase in total STAT3 between 6 to 24 hours after injection (STAT3). (B) An increase in STAT3 phosphorylation was detected after PBS injection with a lesser amplitude and shorter duration than CT-1 treatment (pSTAT3). There was no alteration in total STAT3 protein after PBS treatment (STAT3). (C) CT-1 injection induced STAT1 phosphorylation occurred within 30 minutes after injection and lasted 24 hours (pSTAT1) with a small, late increase in total STAT1 protein (STAT1).

Figure 5.

 

CT-1 induced phosphorylation of Erk1/2. Immunoblot analyses were performed to detect the phosphorylation of Erk1/2 at 0 (control), 0.5, 1, 6, 12, 24, and 48 hours after intravitreal injection of CT-1 (2 μg in 2 μL PBS) in PD9 S334ter-3 rats. (A) CT-1 induced a significant increase in Erk1/2 phosphorylation (ppERKs), which was detected within 30 minutes and lasted 12 hours, with a peak occurring at 1 hour after injection. No changes in the total Erk1/2 protein were observed (ERKs). (B) PBS injection also induced an increase in Erk1/2 phosphorylation, but it was of less amplitude and shorter duration than CT-1 treatment (ppERKs). There were no changes in total Erk1/2 protein after PBS injection (ERKs). (C) No alteration in Akt phosphorylation (pAKT) or total Akt protein (AKT) was detected after injection of CT-1.

Figure 6.

 

Localization of CT-1 induced STAT3 phosphorylation. Cryosections of an untreated control retina (from the right eye of a PD9 wild-type Sprague-Dawley rat; A) or a retina treated with CT-1 (from the left eye of the same animal, 1 hour after injection of CT-1; B) were subjected to immunocytochemical analysis using phospho-STAT3–specific antibodies and confocal microscopy. In the control retina, immunostaining for phospho-STAT3 was mainly detected in the nuclei of retinal ganglion cells, and some weak staining was also present in cells in the INL (A). CT-1 treatment induced a dramatic increase in STAT3 phosphorylation in a specific band of cells in the INL (B). Double-labeling experiments were performed using antibodies against pSTAT3 (C, green) and glutamine synthetase (GS), a Müller-cell–specific marker (D, red). The immunoreactivities of pSTAT3 (green) and GS (red) are clearly colocalized in these cells (E, yellow). GCL: ganglion cell layer. Scale bars: (A, B) 50 μm; (C–E) 20 μm.

The authors thank Yun Liu and Xinyu Zhao for excellent technical assistance.